Candel Therapeutics (CADL) Corporate presentation summary

Pipeline overview and clinical programs

• Aglatimagene besadenovec (CAN-2409) is an off-the-shelf immunotherapy with positive phase 3 data in prostate cancer, and phase 2a data in pancreatic and NSCLC, with multiple FDA designations and a "pipeline in a product" strategy advancing in several large indications.

• Linoserpaturev (CAN-3110) is an oncolytic HSV-1 virus with proof of concept in recurrent high-grade glioma, Fast Track and Orphan Drug Designations, and potential for expansion beyond brain cancers.

• The pipeline includes additional discovery programs for solid tumors and is supported by a strong executive team and advisory board.

Financial position and corporate highlights

• Cash and cash equivalents of $194.8 million as of March 31, 2026, with expected runway into Q1 2028.

• Secured a $130 million term loan facility and a $100 million royalty funding agreement, contingent on aglatimagene approval.

• Intellectual property protection extends to 2034 for aglatimagene and 2036 for linoserpaturev, with 12 years of data exclusivity.

Aglatimagene in prostate cancer: clinical and commercial insights

• Phase 3 trial in intermediate- to high-risk localized prostate cancer (n=745) met its primary endpoint, showing a 30% risk reduction in disease recurrence or death (HR 0.70, p=0.0155).

• Significant improvements in prostate cancer-specific DFS (HR 0.62, p=0.0046), PSA nadir rates, and pathological complete response at 2 years (80.4% vs 63.6%, p=0.0015).

• Well-tolerated safety profile with lower rates of serious adverse events and treatment discontinuation compared to placebo.

• U.S. addressable market estimated at $10–16 billion, with payor feedback supporting broad reimbursement and pricing in line with other prostate cancer therapies.

• Precommercialization activities and BLA submission planned for Q4 2026.